Top latest Five Ecstasy à vendre près de moi Urban news
They prepare to complete this 2nd phase III review by the top of this calendar year. After the period III is total, MAPS will make an application for FDA acceptance for MDMA therapy. They foresee FDA approval to come in late 2023. After it is accredited, the DEA will have 3 months to re-agenda or de-schedule MDMA from its recent Program-one status.